PubMed Central
metadata only
CC BY 4.0
Rapid Fc-mediated surface modification of liposomes with antibodies for selective targeting of pancreatic tumors(☆)
This study introduces a versatile platform for targeted drug delivery that addresses the complexities of conventional immunoliposome preparation. Traditional methods for conjugating a monoclonal antibody (mAb) to the surface of liposomes require target-specific chemical modification for each antibod
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Ligand-modified multifunctional liposome-based targeted delivery platform: a multimodal cancer combination therapy strategy.#433841
- Adebrelimab Combined With Irinotecan Liposomal (II), Oxaliplatin, and 5-FU/LV Conversion Therapy for Locally Advanced Pancreatic Cancer#1307795
- Targeted delivery platforms for in vivo immune cell engineering: emerging strategies for cancer immunotherapy.#1220890
- Bioequivalence Study of Irinotecan Liposome Injection in Chinese Advanced Pancreatic Cancer.#900705
- Breaking Through the Limits: Nanomedicine at the Service of New Drug Combinations to Tackle Pancreatic Cancer#333937
Record · ID 1360154
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive